The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Grow Between 2026 And 2030?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market has experienced significant expansion in recent years. This market is anticipated to increase from $8.43 billion in 2025 to $8.92 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.8%. Factors such as prostate cancer prevalence, hormone therapy resistance, oncology drug innovation, hospital-based cancer care, and the aging male population are credited with its past growth.
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market is set to experience substantial growth in the upcoming years. It is projected to expand to $11.04 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. The expansion anticipated during this period can be ascribed to several factors, including biomarker-driven treatment approaches, advanced targeted therapies, the adoption of oral oncology, the widening oncology pipeline, and personalized cancer care. Furthermore, significant developments expected in the forecast period involve a rising utilization of androgen receptor inhibitors, the proliferation of PARP inhibitor therapies, an increase in combination treatment regimens, a greater emphasis on precision oncology, and a shift towards oral oncology drugs.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp
Which Important Drivers Are Guiding The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Growth?
The increasing occurrence of prostate cancer is projected to drive the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the future. Prostate cancer is defined as a malignancy that forms within the prostate gland, which is a small male gland situated beneath the bladder and anterior to the rectum. This growth in prostate cancer cases is linked to an aging demographic, given that the likelihood of developing the condition rises considerably with advancing age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are instrumental in addressing prostate cancer by focusing on late-stage forms of the illness that have become unresponsive to standard hormone treatments. These therapies enhance patient results through decelerating disease advancement and alleviating symptoms, consequently improving the quality of life. As an illustration, in October 2025, data from NHS Digital, a UK-based government agency tasked with healthcare data and statistics, indicated 58,137 new prostate cancer diagnoses in England during 2023, which signifies a 6 percent rise from 2022. Consequently, the expanding incidence of prostate cancer is propelling the market growth for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics.
How Is The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Categorized Across Its Segment Groups?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –
1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectable, Intravenous
3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals
What Trends Are Influencing The Evolution Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
Companies operating primarily within the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are prioritizing the creation of innovative products and securing authorizations, such as dual-action tablets, to boost therapeutic effectiveness and patient results. Dual-action tablets are defined as sophisticated formulations that integrate two medicinal compounds in a single dose to concurrently address various mechanisms in castration-resistant prostate cancer (CRPC) treatment. For example, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, obtained authorization from the U.S. Food and Drug Administration (FDA) for Akeega, an innovative medication intended for managing adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega functions as a targeted therapy that unites a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), designed specifically for individuals presenting BRCA mutations. Administered in conjunction with prednisone, it markedly improves radiographic progression-free survival (rPFS) in contrast to sole conventional hormonal treatment.
Which Firms Are Influencing Competition In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.
Get The Full Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report:
Which Region Is The Largest In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market 2026, By The Business Research Company
Prostate Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Urothelial Carcinoma Treatment Market Report 2026
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model